First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
|Podcasts|September 25, 2019
Perusing Progress Made in Ovarian Cancer Treatment Paradigm in Pasadena
Author(s)Onclive Team
We traveled to Pasadena, California, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from City of Hope faculty.
Advertisement
We recently traveled to Pasadena, California, for a State of the Science Summit™ on Ovarian Cancer. At the meeting, faculty from City of Hope discussed the necessity of genetic testing as well as the latest data regarding the use of PARP inhibitors, immunotherapy, chemotherapy, and surgical debulking while explaining how these data can be interpreted in clinical practice.
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5